Intrommune Logo Only - 250k.jpg
Media Alert: Interest in Peanut Allergy Market Heats up in the Wake of Aimmune/Nestlé Deal
01 sept. 2020 15h55 HE | Intrommune Therapeutics
NEW YORK, Sept. 01, 2020 (GLOBE NEWSWIRE) -- The recent $2.6 billion acquisition of Aimmune by Nestlé Health Science has helped shed light on the global peanut allergy problem. In January 2020,...
BES_Mark.jpg
AIMMUNE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of AIMT and Encourages Investors to Contact the Firm
31 août 2020 12h37 HE | Bragar Eagel & Squire
NEW YORK, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Supports Outcome of FDA Allergenic Product Advisory Committee Vote
16 sept. 2019 14h25 HE | Intrommune Therapeutics
New York, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly immunotherapy platform for the treatment of peanut and...